Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Biomed Pharmacother. 2022 Aug;152:113207. doi: 10.1016/j.biopha.2022.113207. Epub 2022 Jun 3.
Alzheimer's disease (AD) is a common neurodegenerative disorder in the elderly characterized by memory loss and cognitive dysfunction. The pathogenesis of AD is complex. One-targeted anti-AD drugs usually fail to delay AD progression. Traditional Chinese medicine records have documented the use of the roots of Panax ginseng (ginseng roots) and its prescriptions to treat dementia. Ginsenoside Rg1, the main ginsenoside component of ginseng roots, exhibits a certain therapeutic effect in the abovementioned diseases, suggesting its potential in the management of AD. Therefore, we combed the pathogenesis of AD and currently used anti-AD drugs, and reviewed the availability, pharmacokinetics, and pharmaceutic studies of ginsenoside Rg1. This review summarizes the therapeutic effects and mechanisms of ginsenoside Rg1 and its deglycosylated derivatives in AD in vivo and in vitro. The main mechanisms include improvement in Aβ and Tau pathologies, regulation of synaptic function and intestinal microflora, and reduction of inflammation, oxidative stress, and apoptosis. The underlying mechanisms mainly involve the regulation of PKC, MAPK, PI3K/Akt, CDK5, GSK-3β, BDNF/TrkB, PKA/CREB, FGF2/Akt, p21WAF1/CIP1, NF-κB, NLRP1, TLR3, and TLR4 signaling pathways. As the effects and underlying mechanisms of ginsenoside Rg1 on AD have not been systematically reviewed, we have provided a comprehensive review and shed light on the future directions in the utilization of ginsenoside Rg1 and ginseng roots as well as the development of anti-AD drugs.
阿尔茨海默病(AD)是一种常见的老年神经退行性疾病,其特征是记忆丧失和认知功能障碍。AD 的发病机制很复杂。单靶点抗 AD 药物通常无法延缓 AD 的进展。传统中药记载有用人参(人参根)及其方剂治疗痴呆的记载。人参根的主要人参皂苷成分人参皂苷 Rg1 在上述疾病中表现出一定的治疗效果,表明其在 AD 管理中的潜在应用价值。因此,我们梳理了 AD 的发病机制和目前使用的抗 AD 药物,并综述了人参皂苷 Rg1 的可用性、药代动力学和药剂学研究。本综述总结了人参皂苷 Rg1 及其去糖衍生物在体内和体外 AD 中的治疗作用和机制。主要机制包括改善 Aβ和 Tau 病理学、调节突触功能和肠道微生物群、减轻炎症、氧化应激和细胞凋亡。潜在机制主要涉及 PKC、MAPK、PI3K/Akt、CDK5、GSK-3β、BDNF/TrkB、PKA/CREB、FGF2/Akt、p21WAF1/CIP1、NF-κB、NLRP1、TLR3 和 TLR4 信号通路的调节。由于人参皂苷 Rg1 对 AD 的作用和潜在机制尚未得到系统综述,我们提供了全面的综述,并为利用人参皂苷 Rg1 和人参根以及开发抗 AD 药物指明了未来的方向。